The findings of this study suggest that treatment response and long-term outcomes may be similar in ERBB2-low and ERBB2-negative cancers and do not support the classification of ERBB2-low breast cancer as a unique disease entity. This evidence concerns the gene ERBB2 and breast carcinoma.